Vincaleukoblastine, 22-oxo- en es it fr

Vincaleukoblastine, 22-oxo- Brand names, Vincaleukoblastine, 22-oxo- Analogs

Vincaleukoblastine, 22-oxo- Brand Names Mixture

  • No information avaliable

Vincaleukoblastine, 22-oxo- Chemical_Formula

C46H56N4O10

Vincaleukoblastine, 22-oxo- RX_link

http://www.rxlist.com/cgi/generic3/vincristine.htm

Vincaleukoblastine, 22-oxo- fda sheet

http://www.accessdata.fda.gov/scripts/cder/onctools/summary.cfm?ID=35

Vincaleukoblastine, 22-oxo- msds (material safety sheet)

Vincaleukoblastine,_22-oxo- MSDS

Vincaleukoblastine, 22-oxo- Synthesis Reference

No information avaliable

Vincaleukoblastine, 22-oxo- Molecular Weight

824.958 g/mol

Vincaleukoblastine, 22-oxo- Melting Point

220 oC

Vincaleukoblastine, 22-oxo- H2O Solubility

No information avaliable

Vincaleukoblastine, 22-oxo- State

Solid

Vincaleukoblastine, 22-oxo- LogP

4.918

Vincaleukoblastine, 22-oxo- Dosage Forms

Liquid; Solution

Vincaleukoblastine, 22-oxo- Indication

For treatment of acute leukaemia, malignant lymphoma, Hodgkin's disease, acute erythraemia, acute panmyelosis

Vincaleukoblastine, 22-oxo- Pharmacology

Vincristine is a vinca alkaloid antineoplastic agent used as a treatment for various cancers including breast cancer, Hodgkin's disease, Kaposi's sarcoma, and testicular cancer. The vinca alkaloids are structurally similar compounds comprised of 2 multiringed units, vindoline and catharanthine. The vinca alkaloids have become clinically useful since the discovery of their antitumour properties in 1959. Initially, extracts of the periwinkle plant (Catharanthus roseus) were investigated because of putative hypoglycemic properties, but were noted to cause marrow suppression in rats and antileukemic effects in vitro. Vincristine binds to the microtubular proteins of the mitotic spindle, leading to crystallization of the microtubule and mitotic arrest or cell death. Vincristine has some immunosuppressant effect. The vinca alkaloids are considered to be cell cycle phase-specific.

Vincaleukoblastine, 22-oxo- Absorption

No information avaliable

Vincaleukoblastine, 22-oxo- side effects and Toxicity

IVN-RAT LD50 1300 mg/kg; IPR-MUS LD50 5.2 mg/kg

Vincaleukoblastine, 22-oxo- Patient Information

PATIENT INFORMATION

Follow the links

http://www.rxlist.com/cgi/generic3/vincristine_wcp.htm

http://www.drugs.com/cons/Vincristine.html

Vincaleukoblastine, 22-oxo- Organisms Affected

Humans and other mammals